ADCs for the treatment of HER2-low breast cancer

Paolo Tarantino, MD, Dana-Farber Cancer Institute, Boston, MA, reflects on the use of antibody-drug conjugates (ADCs) for the treatment of HER2-low breast cancer, including trastuzumab duocarmazine which was evaluated in the TULIP trial (NCT03262935), where it demonstrated activity in HER2-low patients, as well as disitamab vedotin which has shown similar response rates. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
Be the first to comment